RxDoctor Payments Data

Jeremy Barber, DO

Gastroenterology · Grand Rapids, MINPI 1417177866

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 68.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $33,272 and has fallen 91.1% since, to $2,947 in 2025. Among gastroenterology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$108,613in general payments, 2019–2025

Across 169 payments — averaging $642.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$75K
  • Pentax Of America, Inc.$19K
  • Siemens Medical Solutions USA, Inc.$7K
  • CSA Medical, Inc$3K
  • US Endoscopy$3K
  • Ambu Inc.$514
  • plus $948 from 11 others

What the payments were for

  • Consulting fees$32,67530%
  • Speaking & faculty fees$61,07156%
  • Travel & lodging$5,8335%
  • Food & beverage$9,0348%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,613 in reported general payments places this provider in the 95th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$90,633
Medicare patients
241
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase61$374,304
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg150$3,790
Pantoprazole Sodium269$3,740
Sucralfate33$2,992
Ursodiol12$2,799
Omeprazole53$912
Esomeprazole Magnesium24$676
Lidocaine Hcl ViscousLidocaine Hcl18$476
Famotidine15$193
Ondansetron OdtOndansetron11$157
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$14$374,30461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →